The field of melanoma biology has experienced a remarkable surge in recent years, owing to progress which has ranged from the most basic laboratory/preclinical discoveries to clinical developments that have begun to transform the management and prognosis for at least certain melanoma patients. Among the key areas that have contributed to this progress are studies relating to signaling and transcriptional pathways that regulate control over differentiation and survival of the melanocyte lineage. The identification of recurring activating mutations in specific signaling factors (B-RAF, N-Ras, c-KIT), amplification of other melanoma oncogenes (MITF, NEDD9), and the crucial recognition that certain of these genomic events occur within melanomas arising with specific clinical features (eg mucosal or acral origin) have led to clear recognition that melanoma is indeed "many different diseases.? While the various subclasses of melanoma may share common features, such as profound invasive and metastatic propensity, it is also likely that sharply focused therapeutic strategies may exploit the functionally critical molecular engines, which distinguish these subclasses. Certain strategies focus upon the immunogenicity and striking clinical opportunities afforded by immune modulation, while others focus more directly on tumor-specific targeting. This issue brings together some of the leaders who have contributed significant insights from basic melanoma biology to progress in the clinic.

Written by the leading names in pediatric oncology and hematology, Nathan and Oski's Hematology and Oncology of Infancy and Childhood offers you the essential tools you need to overcome the unique challenges and complexities of childhood cancers and hematologic disorders. Meticulously updated, this exciting full-color, two-volume set brings together the pathophysiology of disease with detailed clinical guidance to provide you with the most comprehensive, authoritative, up-to-date information for diagnosing and treating children. Form a definitive diagnosis and create the best treatment plans possible with comprehensive coverage of all pediatric cancers, including less-common tumors, as well as all hematologic disorders, including newly recognized ones. Develop a thorough, understanding of the underlying science of diseases through summaries of relevant pathophysiology balanced with clear, practical clinical guidance. Nathan and Oski's is the only comprehensive product on the market that relates pathophysiology in such depth to hematologic and oncologic diseases affecting children. Quickly and effortlessly access the key information you need with the help of a consistent organization from chapter to chapter and from volume to volume. Stay at the forefront of your field thanks to new and revised chapters covering topics such as paroxysmal nocturnal hemoglobinuria, lysosomal storage diseases, childhood genetic predisposition to cancer, and oncology informatics. Learn about the latest breakthroughs in diagnosis and management, making this the most complete guide in pediatric hematology and oncology. Discover the latest in focused molecularly targeted therapies derived from the exponential growth of knowledge about basic biology and genetics underlying the field. Rely on it anytime, anywhere! Access the full text, images, and more at Expert Consult.

David Fisher, MD, PhD, and an authoritative panel of academic, cutting-edge researchers review and summarize the current state of the field. Describing the broad roles of tumor suppressors from a perspective based in molecular biology and genetics, the authors detail the major suppressors and the pathways they regulate, including cell cycle progression, stress responses, apoptosis, and responses to DNA damage. Leading-edge and forward-looking, Tumor Suppressor Genes in Human Cancer illuminates what is currently known of tumor suppressor genes and their regulation, work that is already beginning to revolutionize cancer target elucidation, drug discovery, and treatment design.

David Fisher, MD, PhD, and an authoritative panel of academic, cutting-edge researchers review and summarize the current state of the field. Describing the broad roles of tumor suppressors from a perspective based in molecular biology and genetics, the authors detail the major suppressors and the pathways they regulate, including cell cycle progression, stress responses, apoptosis, and responses to DNA damage. Leading-edge and forward-looking, Tumor Suppressor Genes in Human Cancer illuminates what is currently known of tumor suppressor genes and their regulation, work that is already beginning to revolutionize cancer target elucidation, drug discovery, and treatment design.